Antiviral Activities of Silymarin and Derivatives

Ching-Hsuan Liu, Alagie Jassey, Hsin-Ya Hsu, Liang-Tzung Lin, Ching-Hsuan Liu, Alagie Jassey, Hsin-Ya Hsu, Liang-Tzung Lin

Abstract

Silymarin flavonolignans are well-known agents that typically possess antioxidative, anti-inflammatory, and hepatoprotective functions. Recent studies have also documented the antiviral activities of silymarin and its derivatives against several viruses, including the flaviviruses (hepatitis C virus and dengue virus), togaviruses (Chikungunya virus and Mayaro virus), influenza virus, human immunodeficiency virus, and hepatitis B virus. This review will describe some of the latest preclinical and clinical studies detailing the antiviral profiles of silymarin and its derivatives, and discuss their relevance for antiviral drug development.

Keywords: antiviral; drug development; flavonolignans; silymarin.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures of silibinin, the 1:1 mixture of silybin A and silybin B.

References

    1. Federico A., Dallio M., Loguercio C., Tsai T.-H., Jeon Y. Silymarin/Silybin and Chronic Liver Disease: A Marriage of Many Years. Molecules. 2017;22:191. doi: 10.3390/molecules22020191.
    1. Dixit N., Kohli K., Ahmad S., Baboota S., Ali J. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J. Pharmacol. 2007;39:172. doi: 10.4103/0253-7613.36534.
    1. Bijak M. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism. Molecules. 2017;22:1942. doi: 10.3390/molecules22111942.
    1. Strader D.B., Bacon B.R., Lindsay K.L., Brecque D.R., Morgan T., Wright E.C., Allen J., Khokar M.F., Hoofnagle J.H., Seeff L.B., et al. Use of complementary and alternative medicine in patients with liver disease. Am. J. Gastroenterol. 2002;97:2391–2397. doi: 10.1111/j.1572-0241.2002.05993.x.
    1. European Medicines Agency Silibinin-C-2′,3-dihydrogensuccinate, Disodium Salt for the Prevention of Recurrent Hepatitis C in Liver Transplant Recipients. [(accessed on 23 March 2019)]; Available online: .
    1. Alter H.J., Seeff L.B. Recovery, persistence, and sequelae in hepatitis C virus infection: A perspective on long-term outcome. Semin. Liver Dis. 2000;20:17–35.
    1. Franco L., Palacios G., Martinez J.A., Vázquez A., Savji N., De Ory F., Sanchez-Seco M.P., Martín D., Lipkin W.I., Tenorio A. First report of sylvatic DENV-2-associated dengue hemorrhagic fever in West Africa. PLoS Negl. Trop. Dis. 2011;5:e1251. doi: 10.1371/journal.pntd.0001251.
    1. Polyak S.J., Morishima C., Shuhart M.C., Wang C.C., Liu Y., Lee D.Y. Inhibition of T-Cell Inflammatory Cytokines, Hepatocyte NF-κB Signaling, and HCV Infection by Standardized Silymarin. Gastroenterology. 2007;132:1925–1936. doi: 10.1053/j.gastro.2007.02.038.
    1. Morishima C., Lohmann V., Pal S., Liu Y., Polyak S.J., Lee D.Y.W., Graf T.N., Oberlies N. Identification of hepatoprotective flavonolignans from silymarin. Proc. Natl. Acad. Sci. USA. 2010;107:5995–5999.
    1. Wagoner J., Negash A., Kane O.J., Martinez L.E., Nahmias Y., Bourne N., Owen D.M., Grove J., Brimacombe C., McKeating J.A., et al. Multiple Effects of Silymarin on the Hepatitis C Virus Lifecycle. Hepatology. 2010;51:1912–1921. doi: 10.1002/hep.23587.
    1. Ahmed–Belkacem A., Ahnou N., Barbotte L., Wychowski C., Pallier C., Brillet R., Pohl R., Pawlotsky J. Silibinin and Related Compounds Are Direct Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase. Gastroenterology. 2010;138:1112–1122. doi: 10.1053/j.gastro.2009.11.053.
    1. Blaising J., Lévy P.L., Gondeau C., Phelip C., Varbanov M., Teissier E., Ruggiero F., Polyak S.J., Oberlies N.H., Ivanovic T., et al. Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell. Microbiol. 2013;15:1866–1882. doi: 10.1111/cmi.12155.
    1. Esser-Nobis K., Romero-Brey I., Ganten T.M., Gouttenoire J., Harak C., Klein R., Schemmer P., Binder M., Schnitzler P., Moradpour D., et al. Analysis of hepatitis C virus resistance to Silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology. 2013;57:953–963. doi: 10.1002/hep.26260.
    1. Gosert R., Egger D., Lohmann V., Bartenschlager R., Blum H.E., Bienz K., Moradpour D. Identification of the Hepatitis C Virus RNA Replication Complex in Huh-7 Cells Harboring Subgenomic Replicons. J. Virol. 2003;77:5487–5492. doi: 10.1128/JVI.77.9.5487-5492.2003.
    1. Liu C.H., Lin C.C., Hsu W.C., Chung C.Y., Lin C.C., Jassey A., Chang S.P., Tai C.J., Tai C.J., Shields J., et al. Highly bioavailable silibinin nanoparticles inhibit HCV infection. Gut. 2017;66:1853–1861. doi: 10.1136/gutjnl-2016-312019.
    1. DebRoy S., Hiraga N., Imamura M., Hayes C.N., Akamatsu S., Canini L., Perelson A.S., Pohl R.T., Persiani S., Uprichard S.L. Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy. J. Viral Hepat. 2016;23:708–717. doi: 10.1111/jvh.12551.
    1. Wagoner J., Morishima C., Graf T.N., Oberlies N.H., Teissier E., Pécheur E.-I., Tavis J.E., Polyak S.J. Differential In Vitro Effects of Intravenous versus Oral Formulations of Silibinin on the HCV Life Cycle and Inflammation. PLoS ONE. 2011;6:e16464. doi: 10.1371/journal.pone.0016464.
    1. Qaddir I., Rasool N., Hussain W., Mahmood S. Computer-aided analysis of phytochemicals as potential dengue virus inhibitors based on molecular docking, ADMET and DFT studies. J. Vector Borne Dis. 2017;54:255.
    1. Webster R.G., Govorkova E.A. Continuing challenges in influenza. Ann. N. Y. Acad. Sci. 2014;1323:115–139. doi: 10.1111/nyas.12462.
    1. Hayden F.G., Sugaya N., Hirotsu N., Lee N., De Jong M.D., Hurt A.C., Ishida T., Sekino H., Yamada K., Portsmouth S., et al. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. N. Engl. J. Med. 2018;379:913–923. doi: 10.1056/NEJMoa1716197.
    1. Gažák R., Purchartová K., Marhol P., Živná L., Sedmera P., Valentova K., Kato N., Matsumura H., Kaihatsu K., Křen V. Antioxidant and antiviral activities of silybin fatty acid conjugates. Eur. J. Med. Chem. 2010;45:1059–1067. doi: 10.1016/j.ejmech.2009.11.056.
    1. Song J., Choi H. Silymarin efficacy against influenza A virus replication. Phytomedicine. 2011;18:832–835. doi: 10.1016/j.phymed.2011.01.026.
    1. Dai J.-P., Wu L.-Q., Li R., Zhao X.-F., Wan Q.-Y., Chen X.-X., Li W.-Z., Wang G.-F., Li K.-S. Identification of 23-(S)-2-Amino-3-Phenylpropanoyl-Silybin as an Antiviral Agent for Influenza A Virus Infection In Vitro and In Vivo. Antimicrob. Agents Chemother. 2013;57:4433–4443. doi: 10.1128/AAC.00759-13.
    1. Zhao J. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: Implications in cancer chemoprevention. Carcinogenesis. 1999;20:2101–2108. doi: 10.1093/carcin/20.11.2101.
    1. Roe B., Hall W.W. Cellular and molecular interactions in coinfection with hepatitis C virus and human immunodeficiency virus. Expert Rev. Mol. Med. 2008;10:10. doi: 10.1017/S1462399408000847.
    1. McClure J., Lovelace E.S., Elahi S., Maurice N.J., Wagoner J., Dragavon J., Mittler J.E., Kraft Z., Stamatatos L., Horton H., et al. Correction: Silibinin Inhibits HIV-1 Infection by Reducing Cellular Activation and Proliferation. PLoS ONE. 2012;7:41832. doi: 10.1371/annotation/78ba072a-6b7a-430a-8fcd-ef020e4fc458.
    1. McClure J., Margineantu D.H., Sweet I.R., Polyak S.J. Inhibition of HIV by Legalon-SIL is independent of its effect on cellular metabolism. Virology. 2014;449:96–103. doi: 10.1016/j.virol.2013.11.003.
    1. Lani R., Hassandarvish P., Chiam C.W., Moghaddam E., Chu J.J.H., Rausalu K., Merits A., Higgs S., VanLandingham D., Abu Bakar S., et al. Antiviral activity of silymarin against chikungunya virus. Sci. Rep. 2015;5:11421. doi: 10.1038/srep11421.
    1. Camini F.C., Da Silva T.F., Caetano C.C.D.S., Almeida L.T., Ferraz A.C., Vitoreti V.M.A., Silva B.D.M., Silva S.D.Q., De Magalhães J.C., Magalhães C.L.D.B. Antiviral activity of silymarin against Mayaro virus and protective effect in virus-induced oxidative stress. Antivir. Res. 2018;158:8–12. doi: 10.1016/j.antiviral.2018.07.023.
    1. Hyun S., Lee S., Ventura W.R., McMenamin J. Knowledge, Awareness, and Prevention of Hepatitis B Virus Infection Among Korean American Parents. J. Immigr. Minor. Heal. 2017;20:943–950. doi: 10.1007/s10903-017-0609-1.
    1. Umetsu T., Inoue J., Kogure T., Kakazu E., Ninomiya M., Iwata T., Takai S., Nakamura T., Sano A., Shimosegawa T. Inhibitory effect of silibinin on hepatitis B virus entry. Biochem. Biophys. Rep. 2018;14:20–25. doi: 10.1016/j.bbrep.2018.03.003.
    1. Wu Y.-F., Fu S.-L., Kao C.-H., Yang C.-W., Lin C.-H., Hsu M.-T., Tsai T.-F. Chemopreventive Effect of Silymarin on Liver Pathology in HBV X Protein Transgenic Mice. Cancer Res. 2008;68:2033–2042. doi: 10.1158/0008-5472.CAN-07-2450.
    1. Tanamly M., Tadros F., Labeeb S., Makld H., Mikhail N., Abdel-Hamid M., Shehata M., Abu-Baki L., Medhat A., Magder L., et al. Randomised double-blinded trial evaluating silymarin for chronic hepatitis C in an Egyptian village: Study description and 12-month results. Dig. Liver Dis. 2004;36:752–759. doi: 10.1016/j.dld.2004.06.015.
    1. Gabbay E., Zigmond E., Pappo O., Hemed N., Rowe M., Zabrecky G., Cohen R., Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: Results of phase II randomized, double-blind placebo controlled clinical trial. World J. Gastroenterol. 2007;13:5317–5323. doi: 10.3748/wjg.v13.i40.5317.
    1. Fried M.W., Navarro V.J., Afdhal N., Belle S.H., Wahed A.S., Hawke R.L., Doo E., Meyers C.M., Reddy K.R., Silymarin N., et al. Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: A randomized controlled trial. JAMA. 2012;308:274–282. doi: 10.1001/jama.2012.8265.
    1. Malaguarnera M., Motta M., Vacante M., Malaguarnera G., Caraci F., Nunnari G., Gagliano C., Greco C., Chisari G., Drago F., et al. Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon alpha and ribavirin. Am. J. Transl. Res. 2015;7:2510–2518.
    1. Malaguarnera G., Bertino G., Chisari G., Motta M., Vecchio M., Vacante M., Caraci F., Greco C., Drago F., Nunnari G., et al. Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability. BMC Psychiatry. 2016;16:398. doi: 10.1186/s12888-016-1115-z.
    1. Loguercio C., Festi D., Loguercio C. Silybin and the liver: From basic research to clinical practice. World J. Gastroenterol. 2011;17:2288–2301. doi: 10.3748/wjg.v17.i18.2288.
    1. Ferenci P., Scherzer T.M., Kerschner H., Rutter K., Beinhardt S., Hofer H., Schöniger–Hekele M., Holzmann H., Steindl–Munda P. Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy. Gastroenterology. 2008;135:1561–1567. doi: 10.1053/j.gastro.2008.07.072.
    1. Guedj J., Dahari H., Pohl R.-T., Ferenci P., Perelson A.S. Understanding silibinin’s modes of action against HCV using viral kinetic modeling. J. Hepatol. 2012;56:1019–1024. doi: 10.1016/j.jhep.2011.12.012.
    1. Biermer M., Berg T. Rapid Suppression of Hepatitis C Viremia Induced by Intravenous Silibinin Plus Ribavirin. Gastroenterology. 2009;137:390–391. doi: 10.1053/j.gastro.2009.02.087.
    1. Rutter K., Scherzer T.-M., Beinhardt S., Kerschner H., Stättermayer A.F., Hofer H., Popow-Kraupp T., Steindl-Munda P., Ferenci P. Intravenous silibinin as ‘rescue treatment’ for on-treatment non-responders to pegylated interferon/ribavirin combination therapy. Antivir. Ther. 2011;16:1327–1333. doi: 10.3851/IMP1942.
    1. Biermer M., Schlosser B., Fülöp B., van Bömmel F., Brodzinski A., Heyne R., Keller K., Sarrazin C., Berg T. High-dose silibinin rescue treatment for HCV-infected patients showing suboptimal virologic response to standard combination therapy. J. Viral Hepat. 2012;19:547–553. doi: 10.1111/j.1365-2893.2011.01572.x.
    1. Dahari H., Shteingart S., Gafanovich I., Cotler S.J., D’Amato M., Pohl R.T., Weiss G., Ashkenazi Y.J., Tichler T., Goldin E., et al. Sustained virological response with intravenous silibinin: Individualized IFN-free therapy via real-time modelling of HCV kinetics. Liver Int. 2015;35:289–294. doi: 10.1111/liv.12692.
    1. Verna E.C., Brown R.S., Jr. Hepatitis C Virus Infection in Liver Transplant Candidates and Recipients. [(accessed on 10 March 2019)]; Available online: .
    1. Neumann U., Biermer M., Eurich D., Neuhaus P., Berg T. Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy. J. Hepatol. 2010;52:951–952. doi: 10.1016/j.jhep.2010.02.002.
    1. Beinhardt S., Rasoul-Rockenschaub S., Scherzer T.M., Ferenci P. Silibinin monotherapy prevents graft infection after orthotopic liver transplantation in a patient with chronic hepatitis C. J. Hepatol. 2011;54:591–592. doi: 10.1016/j.jhep.2010.09.009.
    1. Eurich D., Bahra M., Berg T., Boas-Knoop S., Biermer M., Neuhaus R., Neuhaus P., Neumann U. Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy. Exp. Clin. Transplant. 2011;9:1–6.
    1. Aghemo A., Bhoori S., De Nicola S., Mazzaferro V., Colombo M. Failure of Intravenous Silibinin Monotherapy to Prevent Hepatitis C Genotype 2A Liver Graft Reinfection. Hepat. Mon. 2012;12:411–414. doi: 10.5812/hepatmon.6135.
    1. Knapstein J., Wörns A.M., Galle P.R., Zimmermann T. Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: A case report. J. Med. Case Rep. 2014;8:257. doi: 10.1186/1752-1947-8-257.
    1. Mariño Z., Crespo G., D’Amato M., Brambilla N., Giacovelli G., Rovati L., Costa J., Navasa M., Forns X. Intravenous silibinin monotherapy shows significant antiviral activity in HCV-infected patients in the peri-transplantation period. J. Hepatol. 2013;58:415–420. doi: 10.1016/j.jhep.2012.09.034.
    1. Rendina M., D’Amato M., Castellaneta A., Castellaneta N.M., Brambilla N., Giacovelli G., Rovati L., Rizzi S.F., Zappimbulso M., Bringiotti R.S., et al. Antiviral activity and safety profile of silibinin in HCV patients with advanced fibrosis after liver transplantation: A randomized clinical trial. Transpl. Int. 2014;27:696–704. doi: 10.1111/tri.12324.
    1. Bárcena R., Moreno A., Rodriguez-Gandia M.A., Albillos A., Arocena C., Blesa C., García-Hoz F., Graus J., Nuño J., López-Hervás P., et al. Safety and anti-HCV effect of prolonged intravenous silibinin in HCV genotype 1 subjects in the immediate liver transplant period. J. Hepatol. 2013;58:421–426. doi: 10.1016/j.jhep.2012.10.009.
    1. Maier I., Wu G.Y., Maier G.Y.W.I. Hepatitis C and HIV co-infection: A review. World J. Gastroenterol. 2002;8:577–579. doi: 10.3748/wjg.v8.i4.577.
    1. Meissner E.G. Update in HIV/HCV Co-Infection in the Direct Acting Antiviral Era. Curr. Opin. Gastroenterol. 2017;33:120–127. doi: 10.1097/MOG.0000000000000347.
    1. Payer B., Reiberger T., Rutter K., Beinhardt S., Staettermayer A., Peck-Radosavljevic M., Ferenci P. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV–HCV coinfected patient. J. Clin. Virol. 2010;49:131–133. doi: 10.1016/j.jcv.2010.07.006.
    1. Braun D., Rauch A., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Metzner K.J., Böni J., Weber R., Fehr J. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients. HIV Med. 2014;15:625–630. doi: 10.1111/hiv.12166.
    1. Braun D.L., Rauch A., Aouri M., Durisch N., Eberhard N., Anagnostopoulos A., Ledergerber B., Müllhaupt B., Metzner K.J., Decosterd L., et al. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients. PLoS ONE. 2015;10:e0133028. doi: 10.1371/journal.pone.0133028.
    1. Woo J.S., Kim T.-S., Park J.-H., Chi S.-C. Formulation and biopharmaceutical evaluation of silymarin using SMEDDS. Arch. Pharmacal. Res. 2007;30:82–89. doi: 10.1007/BF02977782.
    1. Wu J.-W., Lin L.-C., Hung S.-C., Chi C.-W., Tsai T.-H. Analysis of silibinin in rat plasma and bile for hepatobiliary excretion and oral bioavailability application. J. Pharm. Biomed. Anal. 2007;45:635–641. doi: 10.1016/j.jpba.2007.06.026.
    1. Wu J.-W., Lin L.-C., Tsai T.-H. Drug–drug interactions of silymarin on the perspective of pharmacokinetics. J. Ethnopharmacol. 2009;121:185–193. doi: 10.1016/j.jep.2008.10.036.
    1. Weyhenmeyer R., Mascher H., Birkmayer J. Study on dose-linearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int. J. Clin. Pharmacol. Ther. Toxicol. 1992;30:134–138.
    1. Kidd P., Head K. A review of the bioavailability and clinical efficacy of milk thistle phytosome: A silybin-phosphatidylcholine complex (Siliphos) Altern. Med. A J. Clin. Ther. 2005;10:193–203.
    1. Voinovich D., Perissutti B., Grassi M., Passerini N., Bigotto A. Solid State Mechanochemical Activation of Silybum marianum Dry Extract with Betacyclodextrins: Characterization and Bioavailability of the Coground Systems. J. Pharm. Sci. 2009;98:4119–4129. doi: 10.1002/jps.21704.
    1. Kosina P., Kren V., Gebhardt R., Grambal F., Ulrichova J., Walterova D. Antioxidant properties of silybin glycosides. Phytother. Res. 2002;16(Suppl. 1):S33–S39. doi: 10.1002/ptr.796.
    1. Mira L., Silva M., Manso C. Scavenging of reactive oxygen species by silibinin dihemisuccinate. Biochem. Pharmacol. 1994;48:753–759. doi: 10.1016/0006-2952(94)90053-1.
    1. Maheshwari H., Agarwal R., Patil C., Katare O.P. Preparation and pharmacological evaluation of silibinin liposomes. Arzneimittelforschung. 2003;53:420–427. doi: 10.1055/s-0031-1297130.
    1. Kumar N., Rai A., Reddy N.D., Raj P.V., Jain P., Deshpande P., Mathew G., Kutty N.G., Udupa N., Rao C.M. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells. Pharmacol. Rep. 2014;66:788–798. doi: 10.1016/j.pharep.2014.04.007.
    1. Li F.-Q., Hu J.-H. Improvement of the Dissolution Rate of Silymarin by Means of Solid Dispersions. Chem. Pharm. Bull. (Tokyo) 2004;52:972–973. doi: 10.1248/cpb.52.972.
    1. Qiu M.-F., Jia W., Li S.-S., Xu Z.-H., Sun X., Wang X.-R., Zhang Y.-Y., Xie G.-X. A new silymarin preparation based on solid dispersion technique. Adv. Ther. 2005;22:595–600. doi: 10.1007/BF02849953.
    1. Li X., Yuan Q., Huang Y., Zhou Y., Liu Y. Development of Silymarin Self-Microemulsifying Drug Delivery System with Enhanced Oral Bioavailability. AAPS PharmSciTech. 2010;11:672–678. doi: 10.1208/s12249-010-9432-x.
    1. Wu W., Wang Y., Que L. Enhanced bioavailability of silymarin by self-microemulsifying drug delivery system. Eur. J. Pharm. Biopharm. 2006;63:288–294. doi: 10.1016/j.ejpb.2005.12.005.
    1. Parveen R., Baboota S., Ali J., Ahuja A., Ahmad S. Stability studies of silymarin nanoemulsion containing Tween 80 as a surfactant. J. Pharm. Bioallied Sci. 2015;7:321–324.
    1. Wang Y., Zhang D., Liu Z., Liu G., Duan C., Jia L., Feng F., Zhang X., Shi Y., Zhang Q. In vitroandin vivoevaluation of silybin nanosuspensions for oral and intravenous delivery. Nanotechnology. 2010;21:155104. doi: 10.1088/0957-4484/21/15/155104.
    1. Hsu W.-C., Ng L.-T., Wu T.-H., Lin L.-T., Yen F.-L., Lin C.-C., Huang L.-T. Characteristics and Antioxidant Activities of Silymarin Nanoparticles. J. Nanosci. Nanotechnol. 2012;12:2022–2027. doi: 10.1166/jnn.2012.5173.
    1. Polyak S.J., Ferenci P., Pawlotsky J.M. Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology. 2013;57:1262–1271. doi: 10.1002/hep.26179.

Source: PubMed

Patrocinadores e Colaboradores

Condições médicas

Intervenções de drogas

3
Se inscrever